TNFRSF9 and ovarian carcinoma: Prior studies have reported that anti-CD137 mAb synergizes with cisplatin, a commonly used chemotherapeutic drug for ovarian cancer, to induce regression of the murine CT-26 colon cancer in 60% of mice [38].